Whales with a lot of money to spend have taken a noticeably bearish stance on Tempus AI. Looking at options history for Tempus AI TEM we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and ...

Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results. Discover how Matt Maley trades sharp reversals-live this Wednesday, May 28 at 6 PM ET. Save your free seat now.

US & Canada, May 28, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the sternal closure systems market is witnessing significant growth owing to the advancements in surgical techniques and the rising incidence of cardiovascular diseases ( CVDs ) .

Why are seniors being targeted in crypto scams? Scammers prey on seniors because they view them as financially secure, trusting and less familiar with rapidly evolving technology.Let's understand why seniors are key targets.Perception of wealth: Many older adults have retirement savings or ...

Toronto, May 28, 2025 ( GLOBE NEWSWIRE ) -- Greater Toronto Area, May 28, 2025 - Yesterday at 2:30PM EST, key leaders from the building and development industry issued an open letter to Prime Minister Carney regarding the urgent need for federal action on the GST rebate and Canada's housing ...

NEW YORK, May 28, 2025 ( GLOBE NEWSWIRE ) --

- Enters interest rate swap agreement to fix borrowing costs with an underlying reference rate of 3.57% on 50% of the term loan -

New data finds novel cell therapy successfully converts "cold" ovarian tumors into "hot," demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts "cold" ovarian tumors into "hot," demonstrating potential to unlock immune ...

JERSEY CITY, N.J., May 28, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, ...

First quarter of 2025 delivers US$1.01 million in revenue, bolstered by strategic investment and global distribution momentum First quarter of 2025 delivers US$1.01 million in revenue, bolstered by strategic investment and global distribution momentum ...